February 24, 2011 — A change in the level of prostate-specific antigen (PSA) — known as PSA velocity — is not a good predictor of prostate cancer. In fact, in the absence of other indications, such as ...
Multiple phase-2 trials in men with biochemically-recurrent prostate cancer (BRPC) have assessed the impact of nonhormonal agents on PSA kinetics. We have previously demonstrated that changes in PSA ...
Unequivocal randomized trial data show that PSA velocity does not benefit decision making in localized prostate cancer. A recent paper suggests that the literature is wrong and that PSA velocity does ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback